Clinical Focus

  • Pediatric Hematology-Oncology

Academic Appointments

Administrative Appointments

  • Rotation Director, Pediatric Hematology Residency Selective (2013 - Present)
  • Undergraduate Pre-Major Advisor, Stanford University (2013 - Present)
  • Clerkship Director, Pediatric Hematology-Oncology Medical School Clerkship (Peds 305A) (2014 - Present)

Honors & Awards

  • Awardee, Regents Scholar (2001)
  • Awardee, Alpha Delta Lambda Honor Society (2001)
  • Awardee, ChildrenÂ’s Hospital of Orange County Resident Teaching Award (2007)
  • Resident, Children's Hospital of Orange County Merle J. Norman Graduating Resident of the Year (2008)
  • Fellow, Krensky Endowed Clinical Fellow (2008-2009)
  • Fellow, Debra and Andrew Rachleff Endowed Fellow (2009-2011)
  • Awardee, Helena Anna Henzl Gabor Young Women in Science Fellowship (2010)
  • Awardee, Stanford Pediatric Research Fund (2011)
  • Awardee, Child Health Research Institute Grant (2012)
  • Awardee, Stanford SPARK (2013)

Boards, Advisory Committees, Professional Organizations

  • Member, Intern Selection Committee (2014 - Present)
  • Committee Member, ITP Consortium of North America (2012 - Present)
  • Member, American Society of Hematology (2008 - Present)
  • Member, American Society of Pediatric Hematology/Oncology (2008 - Present)

Professional Education

  • Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2013)
  • Fellowship:Lucile Packard Children's Hospital (2011) CA
  • Board Certification: Pediatrics, American Board of Pediatrics (2008)
  • Residency:Children's Hospital of Orange County (2008) CA
  • Medical Education:New York Medical College (2005) NY

Research & Scholarship

Current Research and Scholarly Interests

Research interests include:
Biomarkers and targeted therapy in pediatric immune thrombocytopenia
Inherited bleeding disorders
Transfusion-related iron overload

Clinical Trials

  • ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP Recruiting

    The purpose of this study is to understand physician treatment decisions in selecting specific second line treatments in pediatric ITP and to determine the effectiveness of different second line ITP treatments. Eligible patients are those ages 1-18 years who are starting on a new second line treatment for ITP, defined as any treatment other than IVIG, steroids, anti-D globulin, or aminocaproic acid. Enrolled patients remain on the study for approximately one year.

    View full details


All Publications

  • Immune Thrombocytopenia in Children Less Than 1 Year of Age: A Single-institution 10-year Experience JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY Lo, C., Wong, W., Glader, B., Jeng, M. 2013; 35 (5): 406-408


    Immune thrombocytopenia (ITP) in children less than one year of age is less well characterized compared to ITP in toddlers and school-age children. We performed a 10-year retrospective review of ITP patients in this age-cohort at our institution. Diagnosis and classification were made according to the 2009 International Working Group criteria. Fourteen infants were identified. Their bleeding scores were Grades 1 to 2 (79%), Grade 3 (22%), Grades 4 to 5 (0%). Eight patients received treatment with a 75% response rate. Three patients (21%) developed chronic ITP. These observations suggest that ITP in very young patients is similar to typical childhood ITP.

    View details for DOI 10.1097/MPH.0b013e3182580ab4

    View details for Web of Science ID 000323224000025

    View details for PubMedID 22767132

  • The Role of Oxidative Stress in Pediatric Immune Thrombocytopenia Lo, C., Zhang, B., Cusmano-Ozog, K., Wong, W., Jeng, M., Cowan, T., Zehnder, J. L. AMER SOC HEMATOLOGY. 2012
  • The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP BLOOD Zhang, B., Lo, C., Shen, L., Sood, R., Jones, C., Cusmano-Ozog, K., Park-Snyder, S., Wong, W., Jeng, M., Cowan, T., Engleman, E. G., Zehnder, J. L. 2011; 117 (17): 4569-4579


    Pediatric immune thrombocytopenia (ITP) is usually self-limited. However, approximately 20% of children develop chronic ITP, which can be associated with significant morbidity because of long-term immunosuppression and splenectomy in refractory cases. To explore the molecular mechanism of chronic ITP compared with acute ITP, we studied 63 pediatric patients with ITP. Gene expression analysis of whole blood revealed distinct signatures for acute and chronic ITP. Oxidative stress-related pathways were among the most significant chronic ITP-associated pathways. Overexpression of VNN1, an oxidative stress sensor in epithelial cells, was most strongly associated with progression to chronic ITP. Studies of normal persons demonstrated VNN1 expression in a variety of blood cells. Exposure of blood mononuclear cells to oxidative stress inducers elicited dramatic up-regulation of VNN1 and down-regulation of PPAR?, indicating a role for VNN1 as a peripheral blood oxidative stress sensor. Assessment of redox state by tandem mass spectrometry demonstrated statistically significant lower glutathione ratios in patients with ITP versus healthy controls; lower glutathione ratios were also seen in untreated patients with ITP compared with recently treated patients. Our work demonstrates distinct patterns of gene expression in acute and chronic ITP and implicates oxidative stress pathways in the pathogenesis of chronic pediatric ITP.

    View details for DOI 10.1182/blood-2010-09-304931

    View details for Web of Science ID 000289984800022

    View details for PubMedID 21325602

  • Development of Antibodies to Human Thrombin and Factor V in a Patient Exposed to Topical Bovine Thrombin PEDIATRIC BLOOD & CANCER Lo, C. Y., Jones, C., Glader, B., Zehnder, J. L. 2010; 55 (6): 1195-1197


    Bovine topical thrombin is commonly used for local hemostasis in pediatric surgery. Acquired inhibitors to coagulation factors, particularly to factor V and bovine thrombin, have been infrequently reported in the pediatric population. We report a 3-year-old male who developed a coagulopathy and clinical bleeding after cardiothoracic surgery, during which bovine topical thrombin was used for local hemostasis. Laboratory tests revealed elevated prothrombin, partial thromboplastin, and thrombin times, and a low factor V activity level. He was found to have both human-thrombin and factor V inhibitors, among the first reported cases of these combined inhibitors secondary to bovine topical thrombin. He was treated with intravenous immunoglobulin and steroids with a rapid and durable response.

    View details for DOI 10.1002/pbc.22699

    View details for Web of Science ID 000283757600028

    View details for PubMedID 20979176

Stanford Medicine Resources: